Esperion Therapeutics (ESPR) News Today $1.61 -0.02 (-1.23%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.31%) As of 03/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period FY2027 Earnings Estimate for ESPR Issued By Zacks ResearchMarch 28 at 2:17 AM | americanbankingnews.comEsperion to Participate in 24th Annual Needham Virtual Healthcare ConferenceMarch 24, 2025 | markets.businessinsider.comVictory Capital Management Inc. Increases Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Victory Capital Management Inc. boosted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 602.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,083 shares of the biMarch 23, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)March 23, 2025 | americanbankingnews.comEsperion aligns with U.S. FDA to initiate Phase 3 trials of bempedoic acidMarch 21, 2025 | markets.businessinsider.comEsperion Therapeutics (NASDAQ:ESPR) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday.March 21, 2025 | marketbeat.comPlatinum Investment Management Ltd. Sells 252,810 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Platinum Investment Management Ltd. cut its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 23.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 840,052 shareMarch 20, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 31.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 932,008 shares ofMarch 19, 2025 | marketbeat.comESPR FY2025 EPS Estimate Boosted by Cantor FitzgeraldEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a note issued to investors on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now antiMarch 15, 2025 | marketbeat.comQ3 Earnings Forecast for ESPR Issued By HC WainwrightEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 EPS estimates for Esperion Therapeutics in a report issued on Tuesday, March 4th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($0.15)March 8, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for ESPR Q1 Earnings?Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, March 4th. HC Wainwright analyst J. Pantginis expects that the biopharmaceuMarch 7, 2025 | marketbeat.comEsperion Bags $5 Mln CSL Seqirus Deal To Commercialize Cholesterol Drugs In Australia, New ZealandMarch 5, 2025 | nasdaq.comEsperion Therapeutics' (ESPR) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Tuesday.March 5, 2025 | marketbeat.comEsperion reports Q4 EPS (11c), consensus (16c)March 4, 2025 | markets.businessinsider.comEsperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comEsperion Therapeutics (NASDAQ:ESPR) Releases Earnings Results, Beats Estimates By $0.04 EPSEsperion Therapeutics (NASDAQ:ESPR - Get Free Report) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04.March 4, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPSEsperion Therapeutics (NASDAQ:ESPR - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.04.March 4, 2025 | marketbeat.comEsperion Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 4, 2025 | globenewswire.comEsperion Therapeutics Q4 2024 Earnings PreviewMarch 3, 2025 | msn.comEsperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in AustraliaMarch 3, 2025 | globenewswire.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of "Moderate Buy" by BrokeragesEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has received a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recoMarch 3, 2025 | marketbeat.comIs Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?March 1, 2025 | msn.comSigma Planning Corp Increases Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Sigma Planning Corp boosted its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 1,455.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 190,441 shares of the biopharmaceutical company's stFebruary 28, 2025 | marketbeat.comEsperion Therapeutics: Little Upside Potential In Their Earlier Generation DrugFebruary 22, 2025 | seekingalpha.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest UpdateEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 31,240,000 shares, a decrease of 8.1% from the January 15th total of 33,980,000 shares. Currently, 16.0% of the shares of the company are sold short. Based on an average trading volume of 6,230,000 shares, the days-to-cover ratio is presently 5.0 days.February 18, 2025 | marketbeat.comEsperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4February 18, 2025 | globenewswire.comEsperion Therapeutics (ESPR) Expected to Announce Earnings on TuesdayEsperion Therapeutics (NASDAQ:ESPR) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comZacks Research Has Negative Forecast for ESPR Q3 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Esperion Therapeutics in a research note issued on Wednesday, February 12th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical cFebruary 17, 2025 | marketbeat.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)February 13, 2025 | globenewswire.comEsperion Therapeutics' (ESPR) Market Outperform Rating Reaffirmed at JMP SecuritiesJMP Securities reissued a "market outperform" rating and issued a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday.February 11, 2025 | marketbeat.comEsperion price target lowered to $4 from $7 at JMP SecuritiesFebruary 11, 2025 | markets.businessinsider.comEsperion stock target cut to $4 by JMP SecuritiesFebruary 11, 2025 | msn.comEsperion stock holds Buy rating, $16 target from H.C. WainwrightFebruary 11, 2025 | msn.comEsperion Therapeutics' (ESPR) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday.February 11, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from AnalystsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a holFebruary 6, 2025 | marketbeat.comEsperion (ESPR) Receives a Sell from Bank of America SecuritiesFebruary 4, 2025 | markets.businessinsider.comWhat is HC Wainwright's Estimate for ESPR FY2028 Earnings?Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at HC Wainwright cut their FY2028 EPS estimates for Esperion Therapeutics in a report released on Thursday, January 23rd. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn $0.16January 27, 2025 | marketbeat.comCautious Outlook on Esperion: Sell Rating Amid Market Challenges for Bempedoic AcidJanuary 23, 2025 | markets.businessinsider.comPromising Potential of Esperion’s Non-Statin Drugs in Cardiovascular Disease ManagementJanuary 23, 2025 | markets.businessinsider.comJMP Securities maintains $7 target on Esperion stockJanuary 23, 2025 | msn.comEsperion Therapeutics' (ESPR) "Market Outperform" Rating Reiterated at JMP SecuritiesJMP Securities reissued a "market outperform" rating and set a $7.00 price objective on shares of Esperion Therapeutics in a research report on Thursday.January 23, 2025 | marketbeat.comBuy Rating for Esperion Based on Strong Clinical Data and Market Adoption of NEXLETOL and NEXLIZETJanuary 23, 2025 | markets.businessinsider.comCantor Fitzgerald Estimates ESPR FY2025 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Esperion Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post earJanuary 23, 2025 | marketbeat.comResearch Analysts Set Expectations for ESPR FY2025 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Esperion Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will earn $0.05 per shaJanuary 22, 2025 | marketbeat.comEsperion Therapeutics CFO sells shares worth $20January 21, 2025 | msn.comEsperion Therapeutics chief commercial officer sells $277 in stockJanuary 21, 2025 | msn.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Position Lifted by Barclays PLCBarclays PLC lifted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 99.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 309,671 shares of the biopharJanuary 18, 2025 | marketbeat.comBank of America Securities Reaffirms Their Sell Rating on Esperion (ESPR)January 16, 2025 | markets.businessinsider.comEsperion stock falls on higher operating expense forecastJanuary 16, 2025 | msn.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Hold" from BrokeragesShares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have received an average rating of "Hold" from the five research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommenJanuary 12, 2025 | marketbeat.com Remove Ads Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Media Mentions By Week ESPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼0.760.78▲Average Medical News Sentiment ESPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼94▲ESPR Articles Average Week Remove Ads Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amphastar Pharmaceuticals News Today 89bio News Today Adaptive Biotechnologies News Today Evotec News Today ARS Pharmaceuticals News Today Ardelyx News Today Ocular Therapeutix News Today Structure Therapeutics News Today Calliditas Therapeutics AB (publ) News Today Iovance Biotherapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
